MBX Biosciences, Inc. (MBX): who owns it and who trades it
As of Nov 16, 2026, MBX insiders reported 7 open-market sales worth $3M and 1 purchase worth $526K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Salomon Azoulay (Chief Medical Officer), with $2.7M. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling MBX Biosciences
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MBX
173 funds and institutions reported MBX shares worth $3.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Frazier Life Sciences Management, L.P. with 14.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6.65M | 14.00% | $367M | No change |
| FMR LLC (Fidelity) | 5.32M | 11.20% | $294M | +81% |
| Wellington Management Group LLP | 4.98M | 10.48% | $275M | +56% |
| NEA Management Company, LLC | 3.61M | 7.61% | $200M | No change |
| Orbimed Advisors LLC | 3.43M | 7.22% | $189M | -6% |
| BlackRock, Inc. | 3.32M | 7.00% | $183M | +13% |
| Paradigm Biocapital Advisors LP | 2.51M | 5.28% | $138M | – |
| Nvp Associates, LLC | 2.14M | 4.50% | $118M | No change |
| Deep Track Capital, LP | 1.73M | 3.65% | $95.6M | -37% |
| Polar Capital Holdings Plc | 1.61M | 3.39% | $88.8M | -1% |
| Vanguard Capital Management LLC | 1.48M | 3.11% | $81.6M | No change |
| Aaron Wealth Advisors LLC | 1.17M | 2.46% | $64.5M | No change |
| Driehaus Capital Management LLC | 1.06M | 2.22% | $58.3M | +4% |
| Kynam Capital Management, LP | 934,799 | 1.97% | $51.6M | No change |
| Woodline Partners LP | 900,092 | 1.89% | $49.7M | No change |
| Eventide Asset Management, LLC | 873,492 | 1.84% | $48.2M | -2% |
| State Street Corp | 864,466 | 1.82% | $47.7M | +10% |
| T. Rowe Price Associates | 814,807 | 1.72% | $45M | -21% |
| Parkman Healthcare Partners LLC | 800,173 | 1.68% | $44.2M | No change |
| Geode Capital Management, LLC | 773,072 | 1.63% | $42.7M | +15% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MBX insiders reported $526K of open-market purchases and $3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Steven L. Hoerter | CEO | Sale | 4,893 | $54.82 | $268K | Form 4 |
| Nov 4, 2026 | Salomon Azoulay | Chief Medical Officer | Sale | 373 | $53.96 | $20.1K | Form 4 |
| Aug 4, 2026 | Salomon Azoulay | Chief Medical Officer | Sale | 370 | $65.77 | $24.3K | Form 4 |
| May 8, 2026 | Salomon Azoulay | Chief Medical Officer | Sale | 55,000 | $38.38 | $2.1M | Form 4 |
| May 8, 2026 | Salomon Azoulay | Chief Medical Officer | Sale | 15,003 | $38.30 | $575K | Form 4 |
| May 6, 2026 | Salomon Azoulay | Chief Medical Officer | Sale | 231 | $29.54 | $6.8K | Form 4 |
| May 6, 2026 | P. Kent Hawryluk | CEO | Sale | 607 | $29.54 | $17.9K | Form 4 |
| Mar 13, 2026 | P. Kent Hawryluk | CEO | Purchase | 18,500 | $28.41 | $526K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Salomon Azoulay | Chief Medical Officer | – | $2.7M | Nov 4, 2026 |
| P. Kent Hawryluk | President & CEO, Director | $526K | $17.9K | May 6, 2026 |
| Steven L. Hoerter | Chairman, President and CEO, Director | – | $268K | Nov 10, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MBX short interest
Moderate short interest. 8.9% of MBX shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short barely changed.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.29M MBX shares were sold short, 8.9% of the shares outstanding, down 3.1% from the report before. At the average daily volume of 542,474 shares, buying them all back would take about 7.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.29M | 8.90% | -3% | 542,474 | 7.9 |
| Oct 15, 2026 | 4.42M | 9.18% | -1% | 592,717 | 7.5 |
| Sep 30, 2026 | 4.47M | 9.27% | +8% | 653,352 | 6.8 |
| Sep 15, 2026 | 4.13M | 8.58% | -1% | 361,137 | 11.4 |
| Aug 31, 2026 | 4.16M | 8.63% | -16% | 409,997 | 10.1 |
| Aug 14, 2026 | 4.95M | 10.28% | -5% | 442,769 | 11.2 |
| Jul 31, 2026 | 5.19M | 10.92% | -10% | 609,309 | 8.5 |
| Jul 15, 2026 | 5.78M | 12.16% | -2% | 930,195 | 6.2 |
| Jun 30, 2026 | 5.90M | 12.41% | +3% | 1.12M | 5.3 |
| Jun 15, 2026 | 5.71M | 12.02% | +19% | 960,306 | 6.0 |
| May 29, 2026 | 4.81M | 10.13% | +12% | 568,896 | 8.5 |
| May 15, 2026 | 4.28M | 9.02% | +6% | 857,788 | 5.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
MBX Biosciences company events
MBX Biosciences filed 15 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 22, 2026LeadershipThe board of directors of MBX Biosciences, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Peter Radovich as a director of the Company. Filing
- Aug 27, 2026AnnouncementThe Company announced the dosing of the first patient in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP). Filing
- Aug 6, 2026AnnouncementThe Company provided an update on its MBX 4291 phase 1 clinical trial. Filing
- Jul 13, 2026LeadershipDeparture of Chief Executive Officer Kent P. Hawryluk will be stepping away from his role as the Company’s Chief Executive Officer and end his services as a member of the Board effective as of July 13, 2026. Filing
- Jun 12, 2026AnnouncementThe Company announced one-year data from the Phase 2 Avail™ and OLE clinical trials of canvuparatide in adult patients with chronic HP. The update is summarized below. Filing
- Jun 5, 2026LeadershipMBX Biosciences, Inc. held its 2026 annual meeting of stockholders. Filing
- May 11, 2026AnnouncementThe Company provided an update on its obesity portfolio, including initial data from the MBX 4291 Phase1 clinical trial and nomination of MBX 5765 as its amycretin prodrug development candidate, as well as an update on the imapextide Phase 2a clinical trial. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Mar 9, 2026AnnouncementThe Company announced completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration. Filing
- Feb 27, 2026LeadershipThe Company and Richard Bartram entered into a separation agreement pursuant to which Mr. Bartram will resign as Chief Financial Officer of the Company. Filing
- Feb 5, 2026AnnouncementMBX Biosciences, Inc., closed on the sale and issuance of an aggregate of 2,250,986 shares of its common stock at a volume weighted average price per share of $38.76 for gross proceeds of approximately $87.1 million. Filing
- Jan 22, 2026LeadershipThe board of directors of MBX Biosciences, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Laurie Stelzer as a director of the Company. Filing
- Jan 12, 2026AnnouncementThe Company announced that it expects to expand its obesity portfolio in 2026 with two additional obesity candidates, with nominations anticipated in the second quarter and third quarter of 2026. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
MBX Biosciences financials
Famous investors that hold MBX
1 of the 50 well-known investors we track reported holding MBX in their latest 13F filing. The largest position is Ken Griffin's, worth $447K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 7,621 | $447K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named MBX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Paradigm BioCapital Advisors LP | 13G/A | 7.8% |
| Nov 16, 2026 | Paradigm BioCapital Advisors LP | 13G/A | 7.8% |
| Nov 5, 2026 | FMR LLC | 13G/A | 15.0% |
| Nov 5, 2026 | FMR LLC | 13G/A | 15.0% |
Questions about MBX Biosciences, Inc. (MBX) stock
Who owns the most MBX stock?
The largest reported owner of MBX Biosciences, Inc. (MBX) is Frazier Life Sciences Management, L.P., with 14.0% of the company. In total, 173 funds and institutions reported holding MBX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are MBX insiders buying or selling?
In the last 12 months, MBX insiders reported 1 open-market purchase worth $526K and 7 sales worth $3M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in MBX?
As of Oct 30, 2026, 4.29M MBX shares were sold short, 8.9% of the shares outstanding, down 3.1% from the report before. At the average daily volume of 542,474 shares, buying them all back would take about 7.9 trading days (days to cover). See the history.
Which famous investors hold MBX?
1 of the 50 well-known investors we track reported MBX in their latest 13F filing, including Ken Griffin. The largest position is worth $447K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.